Clinical trials: MACULAR EDEMA
Choroidal Melanoma
Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
The purpose of the study is to investigate the safety and tolerability of the anti-VEGF (vascular endothelial cell growth factor) treatment, ranibizumab, in combination with proton beam irradiation for the treatment of choroidal…
- Trial name
- NCT00765921
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Diabetic Macular Edema
Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema
PURPOSE: To evaluate the effect of the vitreous in response to intravitreal (IV) injections of ranibizumab 0.5 mg/0.05ml (Lucentis; Genentech, South San Francisco, CA) for the treatment of diabetic macular edema (DME).
- Trial name
- DEVITRA (NCT04387604)
- Testing
- Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]
- Where
- Portugal
- Volunteers
- 50 people
- Sponsor
- Centro Hospitalar do Porto
Macular Edema, Retinal Vein Occlusion
A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of macular edema associated with retinal vein occlusion.
- Trial name
- NCT00168298
- Testing
- 700 µg Dexamethasone, 350 µg Dexamethasone
- Where
- 13 sites in United States, Brazil and 11 more
- Volunteers
- 668 people
- Sponsor
- Allergan
Diabetic Macular Edema (DME)
Zhuochuming®-3T&E-DME Study (Treatment-naïve Patients)
The goal of this clinical trial is to understand whether Zhuochuming® (Aflibercept Intravitreal Injection) using a 3 loading doses followed by a treat-and-extend regimen (3+T\&E) can treat patients with diabetic macular edema…
- Trial name
- NCT07612904
- Testing
- Aflibercept Intravitreous Injection
- Where
- China
- Volunteers
- 186 people
- Sponsor
- The Third Peoples Hospital of Dalian
Cystoid Macular Edema Following Cataract Surgery
PCME Prevention in Patients With NPDR
Pseudophakic cystoid macular edema (PCME), or Irvine-Gass syndrome, is retinal thickening of the macula, which usually develops within 3 months after surgery, with a peak incidence between 4 and 6 weeks.
- Trial name
- NCT04940338
- Testing
- Bromfenac Ophthalmic 0.09% Ophthalmic Solution, Dexamethasone Ophthalmic, Phacoemulsification surgery (PHACO)
- Where
- Croatia
- Volunteers
- 90 people
- Sponsor
- Klinički Bolnički Centar Zagreb
Diabetic Macular Oedema
Quantification of Rising the Osmotic Pressure in Diabetic Intraretinal Fluid Accumulation (Diabetic Macular Oedema)
Diabetic macular oedema is characterized by fluid accumulation in the retinal tissue from leaking retinal vessels, the capillaries. This state can lead to severe visual loss and blindness.
- Trial name
- NCT00333671
- Testing
- Glycerol
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Glostrup University Hospital, Copenhagen
Diabetic Macular Edema (DME)
Integrative Liver-Targeted Therapy for Diabetic Macular Edema: Using "Tauroursodeoxycholate" or Traditional Chinese Medicine.
Diabetic macular edema is seen in the later stages of diabetic retinopathy with current conventional therapies targeting local vascular dysfunction.
- Trial name
- NCT07457632
- Testing
- Tauroursodeoxycholate (TUDCA), Traditional Chinese Medicine (mQJDHW)
- Sponsor
- University of Alabama at Birmingham
Artificial Intelegence, Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus
Application of Artificial Intelligence in Early Detection of Eye Complications in Diabetics
The goal of this pragmatic trial is to test the benefit of using artificial intelligence-based eye screening i.e, a fundus camera device in the early detection of eye complications in diabetics.
- Conditions
- Artificial Intelegence, Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus, Macular Edema Due to Type 2 Diabetes Mellitus
- Trial name
- AI (NCT05655117)
- Testing
- AI based eye screening
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- The New Model of Care, Hail Health Cluster
Branch Retinal Vein Occlusion
601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to macular edema secondary to BRVO
- Trial name
- NCT04667897
- Testing
- 601 1.25mg, Ranibizuman 0.5 mg
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Retinal Disease
Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice
The study aims to collect data on the safety and use of intravitreal aflibercept injections into the eye for the treatment of eye disorders that cause blurred vision or a blind spot due to abnormal or blocked blood vessels.
- Trial name
- MAIA (NCT04137120)
- Testing
- Aflibercept (BAY86-5321, Eylea)
- Where
- Mexico
- Volunteers
- 73 people
- Sponsor
- Bayer
Macular Edema
Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)
To evaluate the efficacy of long-term treatment with 2 mg aflibercept via different intravitreal (IVT) treatment regimens to participants with DME pretreated with 2 mg aflibercept every 8 weeks after 5 initial monthly injections…
- Trial name
- VIOLET (NCT02818998)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- 64 sites in Austria, Canada and 12 more
- Volunteers
- 463 people
- Sponsor
- Bayer
Diabetic Macular Edema
Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy
The purpose of the study is to determine whether concentrations of FOV2304 (high dose or low dose) administered in the eye are more effective than placebo in treating patients with diabetic macular edema, following 12 weeks of…
- Trial name
- NCT01319487
- Testing
- 2304 Eye Drops High Dose, 2304 Eye Drops Low Dose
- Where
- 65 sites in United States, Australia and 8 more
- Volunteers
- 267 people
- Sponsor
- Fovea Pharmaceuticals SA
Anesthesia, Local, Intravitreal Injection
Cooling Anesthesia for Intravitreal Injection
The purpose of this clinical study is to evaluate the safety and efficacy of cooling anesthesia application to the eye as anesthesia for intravitreal injection using a novel cooling anesthesia device and determine the effects of…
- Conditions
- Anesthesia, Local, Intravitreal Injection, Macular Degeneration, Diabetic Macular Edema
- Trial name
- COOL-1 (NCT03732287)
- Testing
- Cooling Anesthesia
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Recens Medical, Inc.
Diabetic Macular Edema
Observational Study of DME Following Scatter Laser Photocoagulation
The development or worsening of macular edema following full scatter photocoagulation is a well recognized occurrence. However, there is limited literature in this regard.
- Trial name
- PRP (NCT00687154)
- Testing
- Scatter Laser Photocoagulation in 1 Sitting, Scatter Laser Photocoagulation in 4 Sittings
- Volunteers
- 155 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Macular Edema
Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema
Diabetic macular oedema (DME) is the main cause of visual impairment (or visual acuity) in patients with diabetic retinopathy, as it leads to progressive thickening of the retina, which in the long term leads to progressive death…
- Trial name
- EMMA (NCT04910503)
- Testing
- Dexamethasone intravitreal implant, Fluocinolone Acetonide Intravitreal Implant
- Where
- France
- Volunteers
- 106 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Diabetic Macular Edema
Glycemic Control and Diabetic Macular Edema
Does diabetic patients' glycemic control affect their response to laser and/or intravitreal injection therapy in terms of visual and anatomical outcomes.
- Trial name
- NCT01358396
- Testing
- Respond to therapy for diabetic macular edema
- Where
- Egypt
- Volunteers
- 52 people
- Sponsor
- Cairo University
Macular Edema
Risk Factors for the Recurrent Postoperative Macular Edema Treated With OZURDEX
Patients who were diagnosed as postoperative CME and administrated with intravitreal OZURDEX injection were reviewed. Outcome will include best-corrected visual acuity (BCVA), intraocular pressure (IOP) and central macular…
- Trial name
- NCT05372562
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University
Diabetic Macular Edema, Diabetic Retinopathy
Prophylactic Effect of Conbercept Intravitreal Injection at the Conclusion of Cataract Surgery for Diabetic Macular Edema
Diabetic macular edema (DME) is an important cause of central vision impairment among people with diabetic retinopathy (DR), which can have a significant adverse effect on daily activities and quality of life.
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy, Cataract Diabetic
- Trial name
- NCT04668703
- Testing
- Conbercept intravitreal injection
- Volunteers
- 40 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Retinal Degenerations
Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
A small percentage of patients with retinal degeneration accumulate fluid in the center of their retina. Previous studies using an oral form of treatment has been successful in decreasing this fluid which improves vision.
- Trial name
- NCT00716586
- Testing
- 2% dorzolamide
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Illinois Chicago
Diabetic Macular Edema
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
The purpose of this study is to evaluate the safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of multiple doses of RO7823653 in participants with DME, administered by intravitreal (IVT) injection as…
- Trial name
- NCT07425522
- Testing
- RO7823653, Faricimab
- Where
- 12 sites in United States
- Volunteers
- 93 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.